Lymph node clues may reveal who benefits from immunotherapy
NCT ID NCT07533357
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This observational study aims to see if a specific type of immune cell (Tpex) in cancer-free lymph nodes can predict how well PD-1 inhibitors work for people with advanced or recurrent esophageal cancer. Researchers will follow 158 participants to compare survival times based on Tpex levels. The goal is to find a better way to identify who will benefit from immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.